Who is a good candidate for this cell therapy for meniscus injury?

Candidates are generally adults 18 or older with an MRI-confirmed grade I–III meniscus injury or knee osteoarthritis, with knee pain or limited function lasting more than three months that hasn't improved with conservative treatment. Patients with a history of severe allergies or malignancy are typically excluded. A specialist should confirm eligibility on a case-by-case basis.

How is this different from meniscus surgery?

Surgery removes or stitches the torn portion of the meniscus, which can reduce its overall size and raise the long-term risk of arthritis. This cell therapy instead aims to regenerate the meniscus tissue in situ, making it especially relevant for patients with white-zone tears who've failed conservative treatment but aren't yet at the point of needing surgery.

Is this treatment safe, and how effective is it based on clinical trials?

A published Phase I dose-escalation clinical trial found this therapy safe over 12 months of follow-up, with meniscus repair confirmed by MRI in up to 83.3% of patients by week 12. As with any early-stage regenerative treatment, individual results vary, and eligibility should be confirmed by a specialist.

top of page

ChinaCurelink
a MedeboundHEALTH Company

FREE CONSULTATION

When Meniscus Surgery Wasn't Enough: How Cell Therapy Achieved In Situ Regeneration in China - A Case Study

ChinaCureLink

Fri Aug 28 2026

6 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page